Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inqovi + Enzalutamide in mCRPC
NCT05037500Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inqovi in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Started Jan 2022; status: terminated.
02
Drugs
inqovi
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05037500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037500.